Literature DB >> 6210141

Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro.

J M Covey, D S Zaharko.   

Abstract

We have investigated the effects of 5-aza-2'-deoxycytidine (DAC) on the growth and clonogenic potential of L1210 leukemia in vitro. Cells were exposed to DAC (0.001-100 micrograms/ml) for periods of 1-120 hrs. Following drug removal, cell growth in suspension culture was measured for up to 7 days, and cell survival was estimated by a colony-formation assay. When cell clonogenicity was plotted against DAC concentration in log-log axis, curves for each exposure time were linear between 0.01 and 0.5 micrograms/ml of DAC, but survival leveled off to a constant percentage for drug concentrations greater than 0.5 micrograms/ml. Percent survival decreased as exposure time increased up to 24 hrs; however, increases in exposure time greater than 24 hrs did not consistently decrease survival any further. At the lower concentrations this leveling of cytotoxicity is due to the spontaneous decomposition of DAC and to the lack of cytotoxicity of the breakdown products. At the higher concentrations the cause of the leveling remains uncertain. Incubation of L1210 with DAC at concentrations greater than 0.5 micrograms/ml for greater than or equal to 24 hrs resulted in total inhibition of measurable cell growth for 72-96 hrs following drug removal. Sequential colony-formation assays at various intervals following drug removal demonstrated a time-dependent increase in cell clonogenicity at a rate approximating the growth rate of untreated L1210 cells. This suggests that despite total cytostasis of the major population of cells, a small fraction of cells is capable of dividing at a near normal rate if removed from the drug environment. Implications of these results for in vivo applications of DAC are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6210141

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.

Authors:  Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Shan Lu; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-08-07       Impact factor: 4.939

2.  Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.

Authors:  Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids.

Authors:  Vijay Raghavan; Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Masayoshi Yamada; Megan Morisada; Vinod Labhasetwar
Journal:  Langmuir       Date:  2015-10-15       Impact factor: 3.882

4.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

5.  Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.

Authors:  Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Cancer Lett       Date:  2013-01-07       Impact factor: 8.679

6.  A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer.

Authors:  Nan Hu; Wei Li; Yidong Hong; Zengtao Zeng; Jingzhou Zhang; Xueyu Wu; Kangjie Zhou; Fenglei Wu
Journal:  Mol Ther Oncolytics       Date:  2021-12-09       Impact factor: 7.200

7.  Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon.

Authors:  Yi-Dong Hong; Jian Zhang; Ming Zhuang; Wei Li; Puy-Uan Wu; Ru-Tian Li; Nan Hu; Bao-Xiang Bian; Zi-Yan Song; Feng-Lei Wu
Journal:  Oncotarget       Date:  2017-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.